Whereas, in our phase II studies, both the GAAD and GALAD (Cobas) algorithms were more sensitive than AFP-L3 in detecting early-stage HCC (70.1% [95% CI: 62.7–76.8%] for both algorithms and 40.8% [95% CI: 33.4–48.5%] for AFP-L3), had higher AUCs (91.4% vs. 91.5% vs. 72.9%) for detecting early-stage HCC and had higher overall true positive rates (25.6% vs. 25.7% vs. 14.9%). This evidence concerns the gene AFP and hepatocellular carcinoma.